Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB206 (Berdazimer Sodium) in Molluscum Contagiosum (B-SIMPLE1)
NCT03927716Phase 3Completed
- Sponsor
- Novan
- Start
- Jun 2019
- Primary completion
- Oct 2019
- Modality
- Polymer-based Nanoparticles, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in molluscum contagiosum (MC) comparing SB206 12% with Placebo (2 arms). Primary endpoint: Complete Clearance of All Treatable MC at 12 weeks. Started Jun 2019; status: completed.
02
Drugs
berdazimer
03
Conditions
molluscum contagiosum (MC)
Beyond the preview
Go deeper on NCT03927716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03927716.